W S Fenton

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia
    W S Fenton
    NIMH, NIH, Bethesda, MD 20892 9621, USA
    Am J Psychiatry 158:2071-4. 2001
  2. ncbi Cost and cost-effectiveness of hospital vs residential crisis care for patients who have serious mental illness
    Wayne S Fenton
    National Institute of Mental Health, 6001 Executive Blvd, Room 8029, MSC 9669, Bethesda, MD 20892 9619, USA
    Arch Gen Psychiatry 59:357-64. 2002
  3. ncbi Mood disorders: cardiovascular and diabetes comorbidity
    Wayne S Fenton
    National Institute of Mental Health, National Institutes of Health, DHHS, Bethesda, Maryland 20892 9621, USA
    Curr Opin Psychiatry 19:421-7. 2006
  4. ncbi Psychiatry residency training, the physician-scientist, and the future of psychiatry
    Wayne Fenton
    Division of Adult Translational Research and Treatment Development, NIMH, 6001 Executive Blvd, Room 6216, MSC 9621, Bethesda, MD 20892-9621, USA
    Acad Psychiatry 28:263-6. 2004
  5. ncbi Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective
    Wayne S Fenton
    National Institute of Mental Health, National Institute of Health, US Department of Health and Human Services, Room 6216, 6001 Executive Boulevard, MSC 9621, Bethesda, MD 20892-9621, USA
    Psychopharmacology (Berl) 169:365-6. 2003
  6. ncbi Person-centered psychiatric care: a tribute to Wayne S. Fenton, MD
    Robert K Heinssen
    Schizophr Bull 33:1149-50. 2007
  7. ncbi New paradigms for treatment development
    Ellen L Stover
    National Institute of Mental Health, Bethesda, MD, USA
    Schizophr Bull 33:1093-9. 2007
  8. ncbi Progress on NIMH initiatives (memorial theme for Wayne Fenton, MD)
    Ellen Stover
    National Institute of Mental Health, USA
    Schizophr Bull 33:1084-5. 2007
  9. ncbi Wayne Fenton, M.D
    Ellen Stover
    NIMH, 6001 Executive Blvd, Rm. 8235, MSC 9669, Bethesda, MD 20892-9669, USA
    Am J Psychiatry 165:177-8. 2008
  10. ncbi Informed Consent in Early Psychosis Research: National Institute of Mental Health workshop, November 15, 2000
    R K Heinssen
    Division of Mental Disorders, Behavioral Research, and AIDS, National Institute of Mental Health, Bethesda, MD 20892 9625, USA
    Schizophr Bull 27:571-83. 2001

Collaborators

Detail Information

Publications29

  1. ncbi A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia
    W S Fenton
    NIMH, NIH, Bethesda, MD 20892 9621, USA
    Am J Psychiatry 158:2071-4. 2001
    ..This study determined if augmentation of neuroleptics with 3 g/day of ethyl eicosapentaenoic acid (EPA) improves symptoms and cognition in patients with schizophrenia or schizoaffective disorder...
  2. ncbi Cost and cost-effectiveness of hospital vs residential crisis care for patients who have serious mental illness
    Wayne S Fenton
    National Institute of Mental Health, 6001 Executive Blvd, Room 8029, MSC 9669, Bethesda, MD 20892 9619, USA
    Arch Gen Psychiatry 59:357-64. 2002
    ....
  3. ncbi Mood disorders: cardiovascular and diabetes comorbidity
    Wayne S Fenton
    National Institute of Mental Health, National Institutes of Health, DHHS, Bethesda, Maryland 20892 9621, USA
    Curr Opin Psychiatry 19:421-7. 2006
    ..This review provides recent findings on comorbidity, summarizes mechanistic hypotheses, and outlines developments in treatment and services...
  4. ncbi Psychiatry residency training, the physician-scientist, and the future of psychiatry
    Wayne Fenton
    Division of Adult Translational Research and Treatment Development, NIMH, 6001 Executive Blvd, Room 6216, MSC 9621, Bethesda, MD 20892-9621, USA
    Acad Psychiatry 28:263-6. 2004
  5. ncbi Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective
    Wayne S Fenton
    National Institute of Mental Health, National Institute of Health, US Department of Health and Human Services, Room 6216, 6001 Executive Boulevard, MSC 9621, Bethesda, MD 20892-9621, USA
    Psychopharmacology (Berl) 169:365-6. 2003
  6. ncbi Person-centered psychiatric care: a tribute to Wayne S. Fenton, MD
    Robert K Heinssen
    Schizophr Bull 33:1149-50. 2007
    ..Through his actions and writings, Wayne Fenton influenced a generation of mental health professionals who aspire to similar professional excellence in all aspects of clinical care...
  7. ncbi New paradigms for treatment development
    Ellen L Stover
    National Institute of Mental Health, Bethesda, MD, USA
    Schizophr Bull 33:1093-9. 2007
    ....
  8. ncbi Progress on NIMH initiatives (memorial theme for Wayne Fenton, MD)
    Ellen Stover
    National Institute of Mental Health, USA
    Schizophr Bull 33:1084-5. 2007
  9. ncbi Wayne Fenton, M.D
    Ellen Stover
    NIMH, 6001 Executive Blvd, Rm. 8235, MSC 9669, Bethesda, MD 20892-9669, USA
    Am J Psychiatry 165:177-8. 2008
  10. ncbi Informed Consent in Early Psychosis Research: National Institute of Mental Health workshop, November 15, 2000
    R K Heinssen
    Division of Mental Disorders, Behavioral Research, and AIDS, National Institute of Mental Health, Bethesda, MD 20892 9625, USA
    Schizophr Bull 27:571-83. 2001
    ..Workshop participants summarized information presented during the meeting into informed consent "bullets" that must be communicated to, and understood and appreciated by, potential research participants...
  11. ncbi Medicine. What are the right targets for psychopharmacology?
    Steven E Hyman
    Harvard University, Boston, MA 02138, USA
    Science 299:350-1. 2003
  12. ncbi Psychiatric epidemiology: it's not just about counting anymore
    Thomas R Insel
    Arch Gen Psychiatry 62:590-2. 2005
  13. ncbi Recovery from schizophrenic psychoses within the northern Finland 1966 Birth Cohort
    Erika Lauronen
    Department of Psychiatry, University of Oulu, P O Box 5000, FIN 90014, Oulu, Finland
    J Clin Psychiatry 66:375-83. 2005
    ..Because of widely disparate findings from follow-up studies, the likelihood of recovery from schizophrenia remains controversial. We report the extent of recovery from schizophrenia in a population-based cohort...
  14. ncbi Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study
    Michael F Green
    Semel Institute for Neuroscience and Human Behavior, UCLA, 300 Medical Plaza, Rm 2263, Los Angeles, CA 90095 6968, USA
    Am J Psychiatry 165:221-8. 2008
    ..e., a co-primary) that is considered functionally meaningful. The goal of the current study was to describe steps to evaluate four potential co-primary measures for psychometric properties and validity...
  15. ncbi Ensuring public trust
    Thomas R Insel
    National Institute of Mental Health, 6001 Executive Boulevard, Room 8235, MSC 9669, Bethesda, MD 20892, USA
    Biol Psychiatry 56:539. 2004
  16. ncbi How should DSM-V criteria for schizophrenia include cognitive impairment?
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Box 3270, Durham, NC 27710, USA
    Schizophr Bull 33:912-20. 2007
    ..Given the current emphasis on the development of cognitive treatments, the evaluation of cognition in schizophrenia is an essential component of mental health education...
  17. ncbi The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization
    Robert S Kern
    Department of Psychology, Geffen School of Medicine, University of California, Los Angeles CA 90073, USA
    Am J Psychiatry 165:214-20. 2008
    ..S. community sample with the battery administered as a unit...
  18. ncbi Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia
    Christopher M Wilk
    Maryland Psychiatric Research Center, Sheppard Pratt Health System, Baltimore, 21228-0747, USA
    Am J Psychiatry 159:838-44. 2002
    ..These data may serve as an informative guide for using the RBANS to evaluate neuropsychological change on the level of the individual subject...
  19. ncbi The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity
    Keith H Nuechterlein
    Department of Psychology, UCLA Semel Institute for Neuroscience and Human Behavior, 300 Medical Plaza, Rm 2251, Los Angeles, CA 90095 6968, USA
    Am J Psychiatry 165:203-13. 2008
    ....
  20. ncbi Placebo response in a double-blind therapeutic supplementation trial in stabilized outpatients with schizophrenia
    Faith B Dickerson
    Schizophr Res 59:97-8. 2003
  21. ncbi Wayne S. Fenton
    Ivan Oransky
    Lancet 368:1568. 2006
  22. ncbi Remembering and appreciating Wayne S. Fenton
    Howard H Goldman
    Psychiatr Serv 57:1367. 2006
  23. ncbi Medication-induced weight gain and dyslipidemia in patients with schizophrenia
    Wayne S Fenton
    Division of Adult Trasnlation Reserach and Treatment Development, NIMH, Bethesda, MD, USA
    Am J Psychiatry 163:1697-704; quiz 1858-9. 2006
  24. ncbi The NIMH-MATRICS consensus statement on negative symptoms
    Brian Kirkpatrick
    Department of Psychiatry and Health Behavior, Medical College of Georgia, USA
    Schizophr Bull 32:214-9. 2006
  25. ncbi Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder
    Joseph R Hibbeln
    Laboratory of Membrane Biochemistry and Biophysics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, Maryland 20852, USA
    Biol Psychiatry 53:431-41. 2003
    ..Prior reports of abnormalities of essential fatty acid metabolism among schizophrenic patients may have been an artifact of patients' smoking behavior and differences in dietary intake of omega-3 fatty acids...
  26. ncbi Shared decision making: a model for the physician-patient relationship in the 21st century?
    Wayne S Fenton
    Acta Psychiatr Scand 107:401-2. 2003
  27. ncbi Changing middle schoolers' attitudes about mental illness through education
    Amy C Watson
    Center for Psychiatric Rehabilitation at Evanston Northwestern Healthcare, 1033 University Place, Suite 450, Evanston, IL 60201, USA
    Schizophr Bull 30:563-72. 2004
    ..These findings suggest that a brief educational program can be an effective intervention to increase knowledge and improve attitudes about mental illness...
  28. ncbi Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria
    Michael F Green
    Neuropsychiatric Institute, Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
    Biol Psychiatry 56:301-7. 2004
    ..The results from this meeting constitute the initial steps for reaching a consensus cognitive battery for clinical trials in schizophrenia...
  29. ncbi Brief cognitive assessment in schizophrenia: normative data for the Repeatable Battery for the Assessment of Neuropsychological Status
    Christopher M Wilk
    Maryland Psychiatric Research Center, PO Box 21247, Baltimore, MD 21228-0747, USA
    Schizophr Res 70:175-86. 2004
    ..CONCLUSIONS: The RBANS is an efficient screening tool for assessing cognitive impairment in patients with SC thereby making it a useful instrument for clinical and research applications...